Auto-generated from public data. Not the firm's stated position.
Nextech Invest appears to focus on life sciences companies developing novel therapeutic modalities, with recent portfolio activity concentrated in oncology and advanced drug delivery technologies across series-a through growth stages. Based on disclosed data, the firm deploys checks in the €3M+ range and seems to target European biotech companies pursuing differentiated approaches to cancer treatment and RNA-based therapeutics.
Generated 1 Oct 2026 from disclosed sectors, stages, and portfolio companies. Firms can update this by emailing [email protected].
Auto-detected from Nextech Invest's website.
Leading biotech entrepreneur and investor with 25+ years building science-based companies, founder/chairman of 9 NASDAQ-listed companies.
11 years at BVF Partners biotech hedge fund, promoted to Managing Director, heads Nextech's public markets effort.
Scientist with passion for emerging technologies in cancer therapies, joined Nextech in 2019 from Third Rock Ventures.
Joined Nextech as intern in 2019, transitioned to Associate in 2021 and Principal in 2025, works at interface of science and business.
30+ year career building and leading investment businesses across multiple regions, joined Nextech in 2016.
Passion for precision medicines in cancer, focused on first and best-in-class targeted therapies regardless of drug modality.
Focus and check size from the firm's website. Website reachable as of Oct 2026.
A fit check scores your pitch against their thesis, stage and ticket. An email draft uses their real deals and thesis, not a template.